In this episode of the Structural Heart podcast, world-renowned cardiothoracic surgeons Dr. Patrick McCarthy and Dr. Dan O'Hair discuss a wide range of topics centered around advancing technology within the surgical and structural heart landscape. The episode starts with Dr. McCarthy and Dr. O'Hair discussing emerging surgical mitral technology alongside how lulls in procedures associated with the COVID-19 pandemic afforded them the extra time to analyze their own program data and better understand which patients benefited most from various cardiac therapies. Next, the conversation shifts from mitral to aortic as they discuss consistent themes and fundamentals that are shared between open-heart aortic valve replacements and transcatheter aortic valve replacements. Both physicians speak to the importance of practicing evidence-based medicine within the cardiovascular space and making decisions rooted in data regarding critical procedures like valve replacements. The episode concludes with light-hearted conversation lessons they wish they had learned earlier in their careers and want to pass along to an emerging generation of cardiovascular physicians. 

Join us for an exciting discussion led by Dr Hemal Gada, an Interventional Cardiologist from UPMC,Pennsylvania, and Dr. Gilbert Tang, a Cardiac Surgeon from Mount Sinai in NY. The conversation will explore how the evolving TAVR landscape shapes  Aortic Stenosis interventions. From the early days to the present, a significant number of patients have been treated, generating a wealth of data on efficiencies, PVL, Hemodynamic impact, and clinical results. What will the data reveal? Will we see a 'TAVR Tsunami'  of patients or a more gradual increase in returning patients? Are there any predictors that can help us identify the right patient? What role does Neosinus flow and thrombosis play in this context?

Don't miss this crucial episode of the Structural Heart Podcast, where we dive into the SMART trial data and evaluate it from two perspectives. We're honored to be joined by cardiothoracic surgeon Dr. Dan O'Hair and one of the SMART trial's PIs, Dr. Hemal Gada. This discussion is not just about the Evolut and Sapien valve platforms but also about what this data means for patients. Stay tuned as they share their critical interpretations of the SMART Trial.

In this episode, we're going to do a deep dive into the Low-Risk TAVR trials for intra-annular Ballon Expandable and Self Expandable supra-annular, and I'm going to be joined by our special guest, Dr. Hemal Gada, renowned interventional cardiologist, and structuralist and president of the Heart and Vascular Institute atIP{MC in Harrisburg, Pennsylvania.

We're gonna cover all kinds of topics like death and stroke thrombosis whose valves are failing, and why.